Sfoglia per Autore
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
2021-01-01 Richardson, Paul G; Oriol, Albert; Larocca, Alessandra; Bladé, Joan; Cavo, Michele; Rodriguez-Otero, Paula; Leleu, Xavier; Nadeem, Omar; Hiemenz, John W; Hassoun, Hani; Touzeau, Cyrille; Alegre, Adrián; Paner, Agne; Maisel, Christopher; Mazumder, Amitabha; Raptis, Anastasios; Moreb, Jan S; Anderson, Kenneth C; Laubach, Jacob P; Thuresson, Sara; Thuresson, Marcus; Byrne, Catriona; Harmenberg, Johan; Bakker, Nicolaas A; Mateos, María-Victoria
Diagnostic and therapeutic challenges in the management of intermediate and frail elderly multiple myeloma patients
2020-01-01 Bonello F.; Boccadoro M.; Larocca A.
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate
2020-01-01 Milani P.; Fazio F.; Basset M.; Berno T.; Larocca A.; Foli A.; Riva M.; Benigna F.; Oliva S.; Nuvolone M.; Rodigari L.; Petrucci M.T.; Merlini G.; Palladini G.
MODULATION OF THE IMMUNE MICROENVIROMENT IN MULTIPLE MYELOMA PATIENTS TREATED WITH DARATUMUMABBASED THERAPY: TUMOR CELL-EXTRINSIC EFFECTS OF DARATUMUMAB TREATMENT
2020-01-01 B. Castella, Mattia D’Agostino, C. Giannotta, S. Oliva, E. Genuardi, Milena Gilestro, M. Ruggeri, P. Corradini, B. Ziccheddu, F. Maura, S. Blasi, N. Bolli, A. Larocca, M. Boccadoro, M. Massaia.
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
2020-01-01 Weisel, Katja; Dimopoulos, Meletios; Moreau, Philippe; Yagci, Munci; Larocca, Alessandra; Kanate, Abraham S; Vural, Filiz; Cascavilla, Nicola; Basu, Supratik; Johnson, Peter; Byeff, Peter; Hus, Marek; Rodríguez-Otero, Paula; Muelduer, Ercan; Anttila, Pekka; Hayden, Patrick J; Krauth, Maria-Theresa; Lucio, Paulo; Ben-Yehuda, Dina; Mendeleeva, Larisa; Guo, Shien; Yu, Xin; Grote, Lara; Biyukov, Tsvetan; Dhanasiri, Sujith; Richardson, Paul
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study
2020-01-01 Mina R.; Belotti A.; Petrucci M.T.; Zambello R.; Capra A.; Di Lullo G.; Ronconi S.; Pescosta N.; Grasso M.; Monaco F.; Cellini C.; Gobbi M.; Ballanti S.; de Fabritiis P.; Mosca-Siez M.L.; Marchetti M.; Liberati A.M.; Offidani M.; Giuliani N.; Ria R.; Musto P.; Romano A.; Sonneveld P.; Boccadoro M.; Larocca A.
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
2020-01-01 Larocca, Alessandra; Mina, Roberto; Offidani, Massimo; Liberati, Anna Marina; Ledda, Antonio; Patriarca, Francesca; Evangelista, Andrea; Spada, Stefano; Benevolo, Giulia; Oddolo, Daniela; Innao, Vanessa; Cangialosi, Clotilde; Bernardini, Annalisa; Musto, Pellegrino; Amico, Valeria; Fraticelli, Vincenzo; Paris, Laura; Giuliani, Nicola; Falcone, Antonietta Pia; Zambello, Renato; De Paoli, Lorenzo; Romano, Alessandra; Palumbo, Antonio; Montefusco, Vittorio; Hajek, Roman; Boccadoro, Mario; Bringhen, Sara
Melflufen for relapsed and refractory multiple myeloma
2020-01-01 Oriol A.; Larocca A.; Leleu X.; Hajek R.; Hassoun H.; Rodriguez-Otero P.; Paner A.; Schjesvold F.H.; Gullbo J.; Richardson P.G.
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation
2020-01-01 Apolito V.; Giaccone L.; Ferrero S.; Larocca A.; Cavallo F.; Coscia M.; Beggiato E.; Butera S.; Martella F.; Dainese C.; Cetani G.; Scaldaferri M.; Cattel F.; Boccadoro M.; Ferrero D.; Bruno B.; Cerrano M.
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
2020-01-01 Oliva S.; D'Agostino M.; Boccadoro M.; Larocca A.
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing
2020-01-01 D'Agostino, Mattia; Zaccaria, Gian Maria; Ziccheddu, Bachisio; Rustad, Even H; Genuardi, Elisa; Capra, Andrea; Oliva, Stefania; Auclair, Daniel; Yesil, Jennifer; Colucci, Paola; Keats, Jonathan J; Gambella, Manuela; Bringhen, Sara; Larocca, Alessandra; Boccadoro, Mario; Bolli, Niccolò; Maura, Francesco; Gay, Francesca
Defining the vulnerable patient with myeloma—a frailty position paper of the European Myeloma Network
2020-01-01 Cook G.; Larocca A.; Facon T.; Zweegman S.; Engelhardt M.
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
2019-01-01 Gambella M.; Omede P.; Spada S.; Muccio V.E.; Gilestro M.; Saraci E.; Grammatico S.; Larocca A.; Conticello C.; Bernardini A.; Gamberi B.; Troia R.; Liberati A.M.; Offidani M.; Rocci A.; Palumbo A.; Cavo M.; Sonneveld P.; Boccadoro M.; Oliva S.
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino
2019-01-01 Gian Maria Zaccaria, Daniela Drandi, Simona Caltagirone, Martina Ferrante, Marco Ghislieri, Daniela Barbero, Marina Ruggeri, Barbara Mantoan, Elisa Genuardi, Daniela Oddolo, Giuseppe Lia, Valentina Griggio, Pierpaola Fenoglio, Mattia D’Agostino, Candida Vitale, Marta Coscia, Benedetto Bruno, Stefania Oliva, Paola Omedè, Alessandra Larocca, Simone Ferrero, Mario Boccadoro
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
2019-01-01 Bringhen, Sara; D'Agostino, Mattia; Paris, Laura; Ballanti, Stelvio; Pescosta, Norbert; Spada, Stefano; Pezzatti, Sara; Grasso, Mariella; Rota-Scalabrini, Delia; De Rosa, Luca; Pavone, Vincenzo; Gazzera, Giulia; Aquino, Sara; Poggiu, Marco; Santoro, Armando; Gentile, Massimo; Baldini, Luca; Petrucci, Maria Teresa; Tosi, Patrizia; Marasca, Roberto; Cellini, Claudia; Palumbo, Antonio; Falco, Patrizia; Hájek, Roman; Boccadoro, Mario; Larocca, Alessandra
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
2019-01-01 Mateos M.-V.; Blacklock H.; Schjesvold F.; Oriol A.; Simpson D.; George A.; Goldschmidt H.; Larocca A.; Chanan-Khan A.; Sherbenou D.; Avivi I.; Benyamini N.; Iida S.; Matsumoto M.; Suzuki K.; Ribrag V.; Usmani S.Z.; Jagannath S.; Ocio E.M.; Rodriguez-Otero P.; San Miguel J.; Kher U.; Farooqui M.; Liao J.; Marinello P.; Lonial S.; Nicol A.; Grigoriadis G.; Catalano J.; LeBlanc R.; Elemary M.; Bahlis N.; Facon T.; Karlin L.; Attal M.; Engelhardt M.; Weisel K.; Mackensen A.; Nagler A.; Ben Yehuda D.; Magen-Nativ H.; Palumbo A.; Cavo M.; Tobinai K.; Chou T.; Kosugi H.; Taniwaki M.; Sunami K.; Ando K.; Ganly P.; Gjertsen B.; Lahuerta J.; Blade J.; Oriol Rocafiguera A.; Mateos M.; Larson S.; Atanackovic D.; Devarakonda S.; Bitran J.; Zonder J.; Morganstein N.; Hay M.; Saylors G.; Kio E.; Oliff I.; Kirkel D.; Shtivelband M.; Yuen C.; Yee A.; Shah J.; Htut M.; Raza S.; Chhabra S.; Stiff P.; Hari P.; Bank B.; Malek E.; Gasparetto C.; Faroun Y.; Kreisle W.; Singhal S.; Rosenblatt J.; Usmani S.; Lee W.; Safah H.; Lutzky J.; Suh J.; Pan D.; Baron A.; Manges R.; Steis R.; Oliveira M.; Moreb J.; Callander N.; Anz B.; Raptis A.; Stampleman L.; Melear J.; Boyd T.; Garbo L.; Klein L.; Shao S.; Lyons R.; McIntyre K.; Tarantolo S.; Yasenchak C.; Yimer H.
Frailty in multiple myeloma: the need for harmony to prevent doing harm
2019-01-01 Zweegman S.; Larocca A.
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
2019-01-01 Saltarella I.; Morabito F.; Giuliani N.; Terragna C.; Omede P.; Palumbo A.; Bringhen S.; De Paoli L.; Martino E.; Larocca A.; Offidani M.; Patriarca F.; Nozzoli C.; Guglielmelli T.; Benevolo G.; Callea V.; Baldini L.; Grasso M.; Leonardi G.; Rizzo M.; Falcone A.P.; Gottardi D.; Montefusco V.; Musto P.; Petrucci M.T.; Dammacco F.; Boccadoro M.; Vacca A.; Ria R.
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies
2019-01-01 Bringhen S.; Mina R.; Petrucci M.T.; Gaidano G.; Ballanti S.; Musto P.; Offidani M.; Spada S.; Benevolo G.; Ponticelli E.; Galieni P.; Cavo M.; Di Toritto T.C.; Di Raimondo F.; Montefusco V.; Palumbo A.; Boccadoro M.; Larocca A.
Moving Toward Continuous Therapy in Multiple Myeloma
2019-01-01 Bonello, Francesca; Cetani, Giusy; Bertamini, Luca; Gay, Francesca; Larocca, Alessandra
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma | 2021 | Richardson, Paul G; Oriol, Albert; Larocca, Alessandra; Bladé, Joan; Cavo, Michele; Rodriguez-Otero, Paula; Leleu, Xavier; Nadeem, Omar; Hiemenz, John W; Hassoun, Hani; Touzeau, Cyrille; Alegre, Adrián; Paner, Agne; Maisel, Christopher; Mazumder, Amitabha; Raptis, Anastasios; Moreb, Jan S; Anderson, Kenneth C; Laubach, Jacob P; Thuresson, Sara; Thuresson, Marcus; Byrne, Catriona; Harmenberg, Johan; Bakker, Nicolaas A; Mateos, María-Victoria | |
| Diagnostic and therapeutic challenges in the management of intermediate and frail elderly multiple myeloma patients | 2020 | Bonello F.; Boccadoro M.; Larocca A. | |
| High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate | 2020 | Milani P.; Fazio F.; Basset M.; Berno T.; Larocca A.; Foli A.; Riva M.; Benigna F.; Oliva S.; Nuvolone M.; Rodigari L.; Petrucci M.T.; Merlini G.; Palladini G. | |
| MODULATION OF THE IMMUNE MICROENVIROMENT IN MULTIPLE MYELOMA PATIENTS TREATED WITH DARATUMUMABBASED THERAPY: TUMOR CELL-EXTRINSIC EFFECTS OF DARATUMUMAB TREATMENT | 2020 | B. Castella, Mattia D’Agostino, C. Giannotta, S. Oliva, E. Genuardi, Milena Gilestro, M. Ruggeri, P. Corradini, B. Ziccheddu, F. Maura, S. Blasi, N. Bolli, A. Larocca, M. Boccadoro, M. Massaia. | |
| Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma | 2020 | Weisel, Katja; Dimopoulos, Meletios; Moreau, Philippe; Yagci, Munci; Larocca, Alessandra; Kanate, Abraham S; Vural, Filiz; Cascavilla, Nicola; Basu, Supratik; Johnson, Peter; Byeff, Peter; Hus, Marek; Rodríguez-Otero, Paula; Muelduer, Ercan; Anttila, Pekka; Hayden, Patrick J; Krauth, Maria-Theresa; Lucio, Paulo; Ben-Yehuda, Dina; Mendeleeva, Larisa; Guo, Shien; Yu, Xin; Grote, Lara; Biyukov, Tsvetan; Dhanasiri, Sujith; Richardson, Paul | |
| Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study | 2020 | Mina R.; Belotti A.; Petrucci M.T.; Zambello R.; Capra A.; Di Lullo G.; Ronconi S.; Pescosta N.; Grasso M.; Monaco F.; Cellini C.; Gobbi M.; Ballanti S.; de Fabritiis P.; Mosca-Siez M.L.; Marchetti M.; Liberati A.M.; Offidani M.; Giuliani N.; Ria R.; Musto P.; Romano A.; Sonneveld P.; Boccadoro M.; Larocca A. | |
| First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials | 2020 | Larocca, Alessandra; Mina, Roberto; Offidani, Massimo; Liberati, Anna Marina; Ledda, Antonio; Patriarca, Francesca; Evangelista, Andrea; Spada, Stefano; Benevolo, Giulia; Oddolo, Daniela; Innao, Vanessa; Cangialosi, Clotilde; Bernardini, Annalisa; Musto, Pellegrino; Amico, Valeria; Fraticelli, Vincenzo; Paris, Laura; Giuliani, Nicola; Falcone, Antonietta Pia; Zambello, Renato; De Paoli, Lorenzo; Romano, Alessandra; Palumbo, Antonio; Montefusco, Vittorio; Hajek, Roman; Boccadoro, Mario; Bringhen, Sara | |
| Melflufen for relapsed and refractory multiple myeloma | 2020 | Oriol A.; Larocca A.; Leleu X.; Hajek R.; Hassoun H.; Rodriguez-Otero P.; Paner A.; Schjesvold F.H.; Gullbo J.; Richardson P.G. | |
| Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation | 2020 | Apolito V.; Giaccone L.; Ferrero S.; Larocca A.; Cavallo F.; Coscia M.; Beggiato E.; Butera S.; Martella F.; Dainese C.; Cetani G.; Scaldaferri M.; Cattel F.; Boccadoro M.; Ferrero D.; Bruno B.; Cerrano M. | |
| Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma | 2020 | Oliva S.; D'Agostino M.; Boccadoro M.; Larocca A. | |
| Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing | 2020 | D'Agostino, Mattia; Zaccaria, Gian Maria; Ziccheddu, Bachisio; Rustad, Even H; Genuardi, Elisa; Capra, Andrea; Oliva, Stefania; Auclair, Daniel; Yesil, Jennifer; Colucci, Paola; Keats, Jonathan J; Gambella, Manuela; Bringhen, Sara; Larocca, Alessandra; Boccadoro, Mario; Bolli, Niccolò; Maura, Francesco; Gay, Francesca | |
| Defining the vulnerable patient with myeloma—a frailty position paper of the European Myeloma Network | 2020 | Cook G.; Larocca A.; Facon T.; Zweegman S.; Engelhardt M. | |
| Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis | 2019 | Gambella M.; Omede P.; Spada S.; Muccio V.E.; Gilestro M.; Saraci E.; Grammatico S.; Larocca A.; Conticello C.; Bernardini A.; Gamberi B.; Troia R.; Liberati A.M.; Offidani M.; Rocci A.; Palumbo A.; Cavo M.; Sonneveld P.; Boccadoro M.; Oliva S. | |
| Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino | 2019 | Gian Maria Zaccaria, Daniela Drandi, Simona Caltagirone, Martina Ferrante, Marco Ghislieri, Daniela Barbero, Marina Ruggeri, Barbara Mantoan, Elisa Genuardi, Daniela Oddolo, Giuseppe Lia, Valentina Griggio, Pierpaola Fenoglio, Mattia D’Agostino, Candida Vitale, Marta Coscia, Benedetto Bruno, Stefania Oliva, Paola Omedè, Alessandra Larocca, Simone Ferrero, Mario Boccadoro | |
| Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial | 2019 | Bringhen, Sara; D'Agostino, Mattia; Paris, Laura; Ballanti, Stelvio; Pescosta, Norbert; Spada, Stefano; Pezzatti, Sara; Grasso, Mariella; Rota-Scalabrini, Delia; De Rosa, Luca; Pavone, Vincenzo; Gazzera, Giulia; Aquino, Sara; Poggiu, Marco; Santoro, Armando; Gentile, Massimo; Baldini, Luca; Petrucci, Maria Teresa; Tosi, Patrizia; Marasca, Roberto; Cellini, Claudia; Palumbo, Antonio; Falco, Patrizia; Hájek, Roman; Boccadoro, Mario; Larocca, Alessandra | |
| Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial | 2019 | Mateos M.-V.; Blacklock H.; Schjesvold F.; Oriol A.; Simpson D.; George A.; Goldschmidt H.; Larocca A.; Chanan-Khan A.; Sherbenou D.; Avivi I.; Benyamini N.; Iida S.; Matsumoto M.; Suzuki K.; Ribrag V.; Usmani S.Z.; Jagannath S.; Ocio E.M.; Rodriguez-Otero P.; San Miguel J.; Kher U.; Farooqui M.; Liao J.; Marinello P.; Lonial S.; Nicol A.; Grigoriadis G.; Catalano J.; LeBlanc R.; Elemary M.; Bahlis N.; Facon T.; Karlin L.; Attal M.; Engelhardt M.; Weisel K.; Mackensen A.; Nagler A.; Ben Yehuda D.; Magen-Nativ H.; Palumbo A.; Cavo M.; Tobinai K.; Chou T.; Kosugi H.; Taniwaki M.; Sunami K.; Ando K.; Ganly P.; Gjertsen B.; Lahuerta J.; Blade J.; Oriol Rocafiguera A.; Mateos M.; Larson S.; Atanackovic D.; Devarakonda S.; Bitran J.; Zonder J.; Morganstein N.; Hay M.; Saylors G.; Kio E.; Oliff I.; Kirkel D.; Shtivelband M.; Yuen C.; Yee A.; Shah J.; Htut M.; Raza S.; Chhabra S.; Stiff P.; Hari P.; Bank B.; Malek E.; Gasparetto C.; Faroun Y.; Kreisle W.; Singhal S.; Rosenblatt J.; Usmani S.; Lee W.; Safah H.; Lutzky J.; Suh J.; Pan D.; Baron A.; Manges R.; Steis R.; Oliveira M.; Moreb J.; Callander N.; Anz B.; Raptis A.; Stampleman L.; Melear J.; Boyd T.; Garbo L.; Klein L.; Shao S.; Lyons R.; McIntyre K.; Tarantolo S.; Yasenchak C.; Yimer H. | |
| Frailty in multiple myeloma: the need for harmony to prevent doing harm | 2019 | Zweegman S.; Larocca A. | |
| Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial | 2019 | Saltarella I.; Morabito F.; Giuliani N.; Terragna C.; Omede P.; Palumbo A.; Bringhen S.; De Paoli L.; Martino E.; Larocca A.; Offidani M.; Patriarca F.; Nozzoli C.; Guglielmelli T.; Benevolo G.; Callea V.; Baldini L.; Grasso M.; Leonardi G.; Rizzo M.; Falcone A.P.; Gottardi D.; Montefusco V.; Musto P.; Petrucci M.T.; Dammacco F.; Boccadoro M.; Vacca A.; Ria R. | |
| Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies | 2019 | Bringhen S.; Mina R.; Petrucci M.T.; Gaidano G.; Ballanti S.; Musto P.; Offidani M.; Spada S.; Benevolo G.; Ponticelli E.; Galieni P.; Cavo M.; Di Toritto T.C.; Di Raimondo F.; Montefusco V.; Palumbo A.; Boccadoro M.; Larocca A. | |
| Moving Toward Continuous Therapy in Multiple Myeloma | 2019 | Bonello, Francesca; Cetani, Giusy; Bertamini, Luca; Gay, Francesca; Larocca, Alessandra |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile